113.18
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $113.18, with a volume of 5.02M.
It is up +0.79% in the last 24 hours and up +1.30% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$112.29
Open:
$112.26
24h Volume:
5.02M
Relative Volume:
0.66
Market Cap:
$140.79B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
23.83
EPS:
4.75
Net Cash Flow:
$9.84B
1W Performance:
-2.60%
1M Performance:
+1.30%
6M Performance:
+16.44%
1Y Performance:
+47.97%
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
113.18 | 139.68B | 28.73B | 5.97B | 9.84B | 4.75 |
![]()
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-25-25 | Upgrade | Needham | Hold → Buy |
Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
Mar-04-25 | Reiterated | Oppenheimer | Outperform |
Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-10-24 | Resumed | BofA Securities | Buy |
Nov-15-24 | Initiated | Wolfe Research | Outperform |
Nov-14-24 | Initiated | Citigroup | Buy |
Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Oct-17-24 | Initiated | Bernstein | Outperform |
Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-01-24 | Reiterated | Maxim Group | Buy |
Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
Feb-22-24 | Downgrade | Truist | Buy → Hold |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
Sep-06-23 | Initiated | HSBC Securities | Reduce |
Jul-24-23 | Reiterated | Barclays | Equal Weight |
May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Apr-28-23 | Resumed | Piper Sandler | Overweight |
Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-13-22 | Resumed | BofA Securities | Neutral |
Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
Oct-28-22 | Reiterated | Cowen | Outperform |
Oct-28-22 | Reiterated | JP Morgan | Overweight |
Oct-28-22 | Reiterated | Jefferies | Buy |
Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
Oct-28-22 | Upgrade | Truist | Hold → Buy |
Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
Feb-02-22 | Reiterated | BofA Securities | Neutral |
Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
Feb-02-22 | Reiterated | Truist | Hold |
Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
Jan-28-22 | Upgrade | Argus | Hold → Buy |
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Dec-06-21 | Initiated | Goldman | Neutral |
Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Nov-19-21 | Resumed | Piper Sandler | Neutral |
Oct-20-21 | Resumed | Cowen | Outperform |
Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
Oct-28-20 | Initiated | UBS | Neutral |
Sep-30-20 | Resumed | Jefferies | Buy |
Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
Jul-31-20 | Reiterated | Credit Suisse | Neutral |
Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
Jul-31-20 | Reiterated | Piper Sandler | Overweight |
Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
Jul-31-20 | Reiterated | SunTrust | Hold |
Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
May-26-20 | Upgrade | SunTrust | Sell → Hold |
May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-01-20 | Downgrade | SunTrust | Hold → Sell |
Apr-27-20 | Downgrade | UBS | Buy → Neutral |
Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Why Gilead Sciences Stock Just Popped - AOL.com
Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment... - Medical Dialogues
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic - Stocktwits
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors - Stock Titan
Gilead Employees Give Back During Month of Service - Gilead Sciences
Trump targets Genentech, Gilead in 'most favored nation' drug-pricing decreeSan Francisco Business Times - The Business Journals
Why is Gilead Sciences Inc. stock attracting strong analyst attentionWealth Building Planner With Proven Results - jammulinksnews.com
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Two Shots A Year: How A New HIV Drug Is Tackling Stigma And Saving Lives - Forbes
Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update - TipRanks
Gilead’s Promising Phase 3 Study in Metastatic Breast Cancer: A Potential Game Changer - TipRanks
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Are Wall Street Analysts Bullish on Gilead Sciences Stock? - Yahoo Finance
How Dr. Toyin Nwafor of Gilead targets HIV disparities - Rolling Out
What data driven models say about Gilead Sciences Inc.’s futureChart Breakout Buy Signal Detection Confirmed - metal.it
Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab - TipRanks
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - MSN
Are Wall Street Analysts Bullish On Gilead Sciences Stock? - Barchart.com
Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360
Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks
BMO says WSJ report on RFK potential headwind for Gilead - Yahoo Finance
AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma
Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks
Gilead price collects profitsForecast today29-07-2025 - Economies.com
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it
What are the technical indicators suggesting about Gilead Sciences Inc.Post Market Planner That Work - jammulinksnews.com
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Why Gilead Sciences Stock Slipped Today - Yahoo Finance
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com
Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu
Gilead Sciences Stock Surges Amid Promising Trials - TipRanks
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Gilead Sciences (GILD) Receives Upgraded Rating from Needham | G - GuruFocus
Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):